|
Post by otherottawaguy on Jan 18, 2019 10:06:43 GMT -5
They previously had a $500M offer on the table for 51% and refused.
|
|
|
Post by otherottawaguy on Jan 4, 2019 16:20:03 GMT -5
Sorry folks been a while but the numbers are starting to get interesting. Will try to keep it updated when I can.
|
|
|
Post by otherottawaguy on Dec 19, 2018 16:11:51 GMT -5
MannKind Announces Commencement of Public Offering WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) (MannKind) today announced that it has commenced an underwritten public offering to issue and sell shares of its common stock and warrants to purchase shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Leerink Partners is acting as sole book-running manager for the offering. The securities described above are being offered by MannKind pursuant to a shelf registration statement on Form S-3 (No. 333-210792) previously filed by MannKind with the Securities and Exchange Commission (SEC) on April 18, 2016 and declared effective on April 27, 2016. The offering will be made only by means of a written prospectus and prospectus supplement that form part of the registration statement. A preliminary prospectus supplement related to the offering and accompanying prospectus will be filed with the SEC and will be available on the SEC website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to the offering, when available, may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: (800) 808-7525, ext. 6132, or by email at syndicate@leerink.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of any securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About MannKind Corporation MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. Forward-Looking Statements Statements in this press release that are not strictly historical in nature, including statements related to the proposed offering by MannKind, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These statements are based upon MannKind’s current expectations. Actual events or results could differ materially from those anticipated in such forward-looking statements due to various factors, including market risks and uncertainties and the satisfaction of customary closing conditions for an offering of securities. For a discussion of these and other factors, please refer to MannKind’s quarterly report on Form 10-Q for the quarter ended September 30, 2018 as well as MannKind’s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. MannKind Contact: Rose Alinaya SVP, Investor Relations 818-661-5000 ir@mannkindcorp.com
|
|
|
Post by otherottawaguy on Dec 19, 2018 16:08:44 GMT -5
Down 10% and counting...
|
|
|
Post by otherottawaguy on Nov 2, 2018 14:17:54 GMT -5
Inhale really deeply, try not to cough...
|
|
|
Post by otherottawaguy on Aug 31, 2018 8:52:40 GMT -5
Wow you got that one off topic for two pages.
See Trepostinil topic if you want to continue its discussion.
OOG
|
|
|
Post by otherottawaguy on Aug 30, 2018 11:45:03 GMT -5
Sorry, second link does not seem to work. You will need to accept the disclaimer and then provide the drug name "Afrezza".
You can also see the causes of the reported incident and other demographics by the dropdown on the top right.
OOG
|
|
|
Post by otherottawaguy on Aug 30, 2018 11:27:36 GMT -5
|
|
|
Post by otherottawaguy on Aug 24, 2018 13:12:06 GMT -5
|
|
|
Post by otherottawaguy on Aug 10, 2018 9:16:46 GMT -5
I think that it already exists, and its called Yahoo for a reason...
|
|
|
Post by otherottawaguy on Jul 30, 2018 13:36:49 GMT -5
|
|
|
Post by otherottawaguy on Jul 28, 2018 12:06:23 GMT -5
Get one of the 3 sided rotating billboards. First shows the message, second side shows the warnings, third shows any other legal mumbo jumbo. Print the entire monogragh if required.
OOG
|
|
|
Post by otherottawaguy on Jul 12, 2018 13:50:25 GMT -5
NEJM???
I can hope can't I?
OOG
|
|
|
Post by otherottawaguy on Jun 22, 2018 15:04:39 GMT -5
Looks like the 13M share at the close was the re-balance...
|
|
|
Post by otherottawaguy on Jun 22, 2018 14:54:51 GMT -5
Looked like 2M+ shares in less than a minute.
OOG
|
|